About Coag-Sense
Coag-Sense is a company based in San Francisco (United States) founded in 2008 by Duane Yamasaki. Coag-Sense has raised $10 million across 2 funding rounds. Coag-Sense offers products and services including PT/INR Monitoring System, PT2, and Accessories. Coag-Sense operates in a competitive market with competitors including Accriva Diagnostics, Diagnostica Stago, Entegrion, Enzyre and MedicQuant ApS, among others.
- Headquarter San Francisco, United States
- Founders Duane Yamasaki
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Coagusense, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
$5 M (USD), Series A
Nov 21, 2016
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Coag-Sense
Coag-Sense offers a comprehensive portfolio of products and services, including PT/INR Monitoring System, PT2, and Accessories.
Provides accurate prothrombin time testing for anticoagulation therapy.
Portable device for direct clot detection in blood testing.
Includes strips and tools for PT/INR system operation.
Funding Insights of Coag-Sense
Coag-Sense has successfully raised a total of $10M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Coag-Sense
Investment portfolio details for Coag-Sense
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Coag-Sense
Detailed financials for Coag-Sense
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Coag-Sense Comparisons
Peer comparison for Coag-Sense
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Coag-Sense
Coag-Sense operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accriva Diagnostics, Diagnostica Stago, Entegrion, Enzyre and MedicQuant ApS, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Near-patient diagnostic systems for coagulation testing are developed.
|
|
| Locked | Locked | Locked |
A portfolio of hemostasis and coagulation diagnostic products is manufactured.
|
|
| Locked | Locked | Locked |
Hemostasis and fluid replacement products are provided for medical applications.
|
|
| Locked | Locked | Locked |
Smart diagnostics devices for blood coagulation analysis are developed.
|
|
| Locked | Locked | Locked |
Diagnostic kits for blood anticoagulant detection are provided.
|
|
| Locked | Locked | Locked |
Anticoagulant reversal agent and small molecules to prevent allergic reactions, traumatic brain injury.
|
Detailed competitors of Coag-Sense
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Coag-Sense
Complete news archive for Coag-Sense
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Coag-Sense
Coag-Sense was founded in 2008 and raised its 1st funding round 8 years after it was founded.
Coag-Sense is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Doug Patterson is the current CEO of Coag-Sense.
Coag-Sense is a funded company, having raised a total of $10M across 2 funding rounds to date.
Coag-Sense was founded in 2008 in San Francisco, United States, focusing on medical devices for coagulation monitoring. The PTINR system is produced with direct micromechanical technology that mimics the WHO tilt-tube method, requiring only 10 microliters of fingerstick blood. Plasma controls can be tested without complications, and results are unaffected by low hemoglobin or hematocrit levels. Operations center on point-of-care diagnostics for anticoagulant therapy management.
Coag-Sense's top competitors include Accriva Diagnostics, Diagnostica Stago and MedicQuant ApS.
Coag-Sense offers PT/INR Monitoring System, PT2, and Accessories.